Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to -$23.7 million.

  • Lineage Cell Therapeutics' Free Cash Flow rose 38.50% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.9 million, marking a year-over-year increase of 9.46%. This contributed to the annual value of -$23.7 million for FY2024, which is 19.09% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Free Cash Flow stood at -$23.7 million for FY2024, which was up 19.09% from -$29.2 million recorded in FY2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Free Cash Flow peaked at $646,000 during FY2022, and registered a low of -$29.2 million during FY2023.
  • Over the past 3 years, Lineage Cell Therapeutics' median Free Cash Flow value was -$23.7 million (recorded in 2024), while the average stood at -$17.4 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Free Cash Flow surged by 102.70% in 2022 and then slumped by 4,626.32% in 2023.
  • Lineage Cell Therapeutics' Free Cash Flow (Yearly) stood at -$19.8 million in 2020, then declined by 20.61% to -$23.9 million in 2021, then spiked by 102.70% to $646,000 in 2022, then crashed by 4,626.32% to -$29.2 million in 2023, then climbed by 19.09% to -$23.7 million in 2024.